In a separate presentation, use of Caris Molecular Intelligence reportedly uncovered distinct targetable biomarkers in biliary tract carcinomas such as extrahepatic cholangiocarcinoma (EHCC), intrahepatic cholangiocarcinoma (IHCC), and gallbladder carcinoma
(GBCA), while also suggesting the potential sensitivity of these rare, aggressive tumor types to novel and conventional therapies.
The following describes the occurrence of Streptococcus bovis bacteremia in a patient with a coexisting gallbladder carcinoma
4) Severe dysplasia and carcinoma in situ have been found in more than 90% of patients with gallbladder carcinoma
Primary gallbladder carcinoma
is a malignant neoplasm with an incidence of 1.
Based upon the CT appearance, the differential diagnosis of adenomyomatosis versus less likely gallbladder carcinoma
or chronic cholecystitis was given.
Topics include: cholecystic venous system and liver metastasis from gallbladder carcinoma
, tumor angiogenesis, external palliative radiotherapy, gallbladder cancer risk in patients with a long common channel, and experimental strategies to treating biliary tract cancer, among others.
5) Gallbladder/bileducts Gallbladder carcinoma
1) revealed a thickened and irregularly enhancing gallbladder wall suggestive of gallbladder carcinoma
and intrahepatic biliary dilation, interpreted as secondary to extension of possible tumor into the porta hepatis.
6%, 4 with stage II disease and 7 with stage IV disease) and 2 patients with gallbladder carcinoma
A second presentation details the therapeutic efficacy of this compound in a mouse model of gallbladder carcinoma
, which is correlated with the down regulation and translocation of erbB2, an EGFR family member.
We found that CTGF protein levels in infiltrating gallbladder carcinoma
were significantly higher than in chronic cholecystitis and dysplasia.
Presenter: Shan Gao, University of Texas MD Anderson Cancer Center Monday, April 14, 2008: -- Session: Histone Deacetylase and Heat Shock Protein Inhibitors Oral presentation: Effects of histone deacetylase (HDAC) inhibitor PCI-24781 on the development of gallbladder carcinoma